CommentaryMOLECULAR DIAGNOSTICS

Regulatory and Reimbursement Innovation

See allHide authors and affiliations

Science Translational Medicine  13 Mar 2013:
Vol. 5, Issue 176, pp. 176cm3
DOI: 10.1126/scitranslmed.3005437

Figures

  • Fig. 1 Pruning the path.

    Shown are schematics of FDA regulatory approval and CMS reimbursement pathways for hypothetical diagnostic products. Parallel review and CED can expedite movement to market.

    CREDIT: Y. HAMMOND/SCIENCE TRANSLATIONAL MEDICINE

Stay Connected to Science Translational Medicine

Navigate This Article